FDA Grants Orphan Drug Designation to Revolutionary Cystic Fibrosis Therapy

Porosome Therapeutics, Inc. enters a new frontier in secretory defect therapeutics through porosome reconstitution

BOSTON--()--Porosome Therapeutics, Inc. (Porosome Therapeutics) today announced the Orphan Drug Designation of its cystic fibrosis therapy by the Food and Drug Administration (FDA).

https://www.businesswire.com/news/home/20250225004448/en/FDA-Grants-Orphan-Drug-Designation-to-Revolutionary-Cystic-Fibrosis-Therapy